| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA625964 | A | cytotoxicity against HIV protease enzyme. | Human immunodeficiency virus | 1 | ALA1133572 | organism-based format | Scientific Literature | |
| 2. | ALA640394 | F | Inhibitory activity against HIV in Alex cells | Human immunodeficiency virus | 32 | ALA1124871 | organism-based format | Scientific Literature | |
| 3. | ALA655578 | F | Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50% | Human immunodeficiency virus | 22 | ALA1132429 | organism-based format | Scientific Literature | |
| 4. | ALA655561 | F | Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50% | Human immunodeficiency virus | 22 | ALA1132429 | organism-based format | Scientific Literature | |
| 5. | ALA683621 | F | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). | Human immunodeficiency virus | 36 | ALA1125739 | organism-based format | Scientific Literature | |
| 6. | ALA683622 | F | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. | Human immunodeficiency virus | 2 | ALA1125739 | organism-based format | Scientific Literature | |
| 7. | ALA683623 | F | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. | Human immunodeficiency virus | 2 | ALA1125739 | organism-based format | Scientific Literature | |
| 8. | ALA690740 | F | In vitro inhibitory activity against HIV was determined | Human immunodeficiency virus | 1 | ALA1127324 | organism-based format | Scientific Literature | |
| 9. | ALA690741 | F | In vitro antiviral activity against human immuno deficiency virus was determined | Human immunodeficiency virus 1 | 6 | ALA1128024 | organism-based format | Scientific Literature | |
| 10. | ALA690742 | F | Compound was evaluated for the cytotoxic concentration against HIV | Human immunodeficiency virus 1 | 5 | ALA1126217 | organism-based format | Scientific Literature | |
| 11. | ALA690744 | F | Antiviral activity was assessed against HIV in MT-4 (human T-helper) cells at a concentration up to 100 ug/mL; inactive | Human immunodeficiency virus | 16 | ALA1132748 | organism-based format | Scientific Literature | |
| 12. | ALA690746 | F | Cytotoxicity of compound was assessed against HIV in MT-4 (human T-helper) cells; inactive | Human immunodeficiency virus | 1 | ALA1132748 | organism-based format | Scientific Literature | |
| 13. | ALA690747 | F | The compound was tested for anti-HIV activity; Range = 5.0-15.0 uM | Human immunodeficiency virus | 1 | ALA1125936 | organism-based format | Scientific Literature | |
| 14. | ALA690748 | F | Compound was tested for cellulr inhibition of HIV was determined | Human immunodeficiency virus | 7 | ALA1128025 | organism-based format | Scientific Literature | |
| 15. | ALA690749 | F | Compound was tested for cellulr inhibition of HIV was determined; Range is 12-25 | Human immunodeficiency virus | 1 | ALA1128025 | organism-based format | Scientific Literature | |
| 16. | ALA690750 | F | Compound was tested for cellulr inhibition of HIV was determined; Range is 25-50 | Human immunodeficiency virus | 1 | ALA1128025 | organism-based format | Scientific Literature | |
| 17. | ALA690751 | F | Compound was tested for cellulr inhibition of HIV was determined; Range is 6-12 | Human immunodeficiency virus | 4 | ALA1128025 | organism-based format | Scientific Literature | |
| 18. | ALA691282 | F | Antiviral activity against HIV-1 protease | Human immunodeficiency virus | 1 | ALA1133572 | organism-based format | Scientific Literature | |
| 19. | ALA686832 | F | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. | Human immunodeficiency virus | 2 | ALA1125739 | organism-based format | Scientific Literature | |
| 20. | ALA686833 | F | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection. | Human immunodeficiency virus | 2 | ALA1125739 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!